Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis

Fig. 3

Copy numbers of SE alleles and RA disease activity scores. The mean values of scores in DAS28-ESR (A), CDAI (B), and SDAI (C) stratified according to the copy number of SE alleles are shown at baseline, 4, 12, and 24 weeks after the start of treatment with tofacitinib or abatacept. RA disease activity scores in DAS28-ESR, CDAI and SDAI were compared between 0 SE alleles and 1 SE allele, 0 SE alleles and 2 SE alleles, and 1 SE allele and 2 SE alleles at each time point in each treatment by the Mann-Whitney U test with Bonferroni corrections. Error bars indicate 95% confidence intervals. P values less than 0.0167 were considered to be significant. †p < 0.0167, 1 SE allele and 2 SE alleles were compared; **p < 0.0167, 0 SE alleles and 2 SE alleles were compared; ***p < 0.0033, 0 SE alleles and 2 SE alleles were compared. CDAI, Clinical Disease Activity Index; DAS28-ESR, Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; SDAI, Simplified Disease Activity Index; RA, rheumatoid arthritis; SE 0, 0 copies of shared epitope alleles; SE 1, 1 copy of shared epitope alleles; SE 2, 2 copies of shared epitope alleles

Back to article page